Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
The AUR87A study found that urine collected biomarkers could accurately predict recurrence of kidney cancer in post-surgery patients.
The phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma.
Tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) combination therapy is emerging as a major therapeutic strategy for advanced clear cell renal cell carcinoma (ccRCC). To define the druggable targets for improvement of TKI and ICI combination therapy in ccRCC, we analyzed a ...
Kidney cancer has caused more than 150,000 deaths in 185 countries around the world and is a serious threat to human life. Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. FDX1, a crucial gene for regulating copper death, plays an important role in tumors. ...
Hand-foot skin reaction (HFSR) is a common adverse effect of vascular endothelial growth factor receptor (VEGFR) inhibitors that significantly impacts patients’ quality of life. Prevention and management of HFSR require individualized approaches, but risk factors remain unclear. This study ...
"The positive results from this phase 3 study of the sintilimab and fruquintinib combination represent a significant advancement in the treatment of advanced renal cell carcinoma,” says Prof Zhisong He.
The study will evaluate the investigational drug product ONC175 (orellanine) in patients with metastatic clear cell or papillary renal cell carcinoma.
An expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors (TKIs) such as lenvatinib/everolimus by highlighting key safety distinctions, including hypertension (HTN), fatigue, and diarrhea. For third-line tivozanib, tolerability ...
... renal cell carcinoma (mRCC) receiving first-line immune checkpoint inhibitor (ICI)-based therapy, according to real-world data presented at the ...
In radiation oncology, renal cancers are experiencing the greatest levels of change and growth, according to James B. Yu.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.